Handelsinvest Investeringsforvaltning Sells 399 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Handelsinvest Investeringsforvaltning lowered its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 34.1% during the 1st quarter, Holdings Channel.com reports. The firm owned 770 shares of the company’s stock after selling 399 shares during the period. Handelsinvest Investeringsforvaltning’s holdings in Medpace were worth $311,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in MEDP. LPL Financial LLC lifted its holdings in Medpace by 115.3% during the third quarter. LPL Financial LLC now owns 23,116 shares of the company’s stock valued at $5,600,000 after purchasing an additional 12,380 shares in the last quarter. Trexquant Investment LP lifted its holdings in Medpace by 283.1% during the third quarter. Trexquant Investment LP now owns 6,410 shares of the company’s stock valued at $1,552,000 after purchasing an additional 4,737 shares in the last quarter. Treasurer of the State of North Carolina lifted its holdings in Medpace by 0.5% during the third quarter. Treasurer of the State of North Carolina now owns 10,230 shares of the company’s stock valued at $2,477,000 after purchasing an additional 50 shares in the last quarter. Synovus Financial Corp lifted its holdings in Medpace by 24.1% during the third quarter. Synovus Financial Corp now owns 1,681 shares of the company’s stock valued at $407,000 after purchasing an additional 326 shares in the last quarter. Finally, Qube Research & Technologies Ltd lifted its holdings in Medpace by 147.3% during the third quarter. Qube Research & Technologies Ltd now owns 24,334 shares of the company’s stock valued at $5,892,000 after purchasing an additional 14,494 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Down 0.3 %

Medpace stock opened at $403.07 on Thursday. The company has a market cap of $12.49 billion, a price-to-earnings ratio of 41.09, a PEG ratio of 2.00 and a beta of 1.36. The firm’s fifty day moving average is $397.80 and its 200 day moving average is $369.78. Medpace Holdings, Inc. has a 52-week low of $227.21 and a 52-week high of $437.39.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, April 22nd. The company reported $3.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.45 by $0.75. The company had revenue of $511.00 million for the quarter, compared to the consensus estimate of $512.39 million. Medpace had a net margin of 15.92% and a return on equity of 59.74%. Medpace’s revenue was up 17.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.27 earnings per share. On average, equities research analysts anticipate that Medpace Holdings, Inc. will post 11.29 earnings per share for the current fiscal year.

Insider Activity at Medpace

In related news, CEO August J. Troendle sold 4,782 shares of the company’s stock in a transaction on Wednesday, May 8th. The shares were sold at an average price of $400.58, for a total transaction of $1,915,573.56. Following the sale, the chief executive officer now owns 716,197 shares of the company’s stock, valued at $286,894,194.26. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Medpace news, CEO August J. Troendle sold 4,782 shares of the business’s stock in a transaction on Wednesday, May 8th. The shares were sold at an average price of $400.58, for a total transaction of $1,915,573.56. Following the transaction, the chief executive officer now owns 716,197 shares in the company, valued at $286,894,194.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO August J. Troendle sold 5,695 shares of the business’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $395.49, for a total transaction of $2,252,315.55. Following the transaction, the chief executive officer now owns 654,656 shares in the company, valued at approximately $258,909,901.44. The disclosure for this sale can be found here. Insiders have sold a total of 29,621 shares of company stock valued at $11,816,852 over the last 90 days. 20.30% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. StockNews.com downgraded shares of Medpace from a “buy” rating to a “hold” rating in a report on Friday, June 7th. Mizuho began coverage on shares of Medpace in a report on Tuesday, May 28th. They issued a “buy” rating and a $435.00 target price on the stock. Deutsche Bank Aktiengesellschaft began coverage on shares of Medpace in a report on Monday, March 18th. They issued a “hold” rating and a $395.00 target price on the stock. TD Cowen began coverage on shares of Medpace in a report on Wednesday, May 29th. They issued a “buy” rating and a $452.00 target price on the stock. Finally, Robert W. Baird boosted their target price on shares of Medpace from $446.00 to $454.00 and gave the stock an “outperform” rating in a report on Wednesday, April 24th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $443.14.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.